Bionial Lifesciences is India's only WHO-GMP certified manufacturer offering a complete proprietary liposomal supplement series. Our BL-LP phospholipid encapsulation platform transforms standard nutrients into high-absorption, premium-positioned products that command 2-4× higher retail pricing for your brand.
Understanding the Science
Liposomal technology is an advanced nutrient delivery system that encapsulates active ingredients inside phospholipid vesicles — tiny, spherical structures composed of the same phospholipid bilayer material that forms human cell membranes. These vesicles, called liposomes, typically measure between 100–200 nanometers in diameter and serve as protective carriers for nutrients that would otherwise be destroyed or poorly absorbed in the gastrointestinal tract.
When you swallow a standard supplement, the active ingredient faces an obstacle course: stomach acid degrades it, enzymes break it down, and the intestinal lining absorbs only a fraction of what remains. Liposomal encapsulation solves this problem by wrapping the nutrient in a phospholipid shell that resists gastric degradation, passes through the intestinal wall intact, and fuses directly with cell membranes to deliver its payload at the cellular level. The result is dramatically higher plasma concentrations and faster onset of action compared to conventional oral supplementation.
4-Stage Delivery Mechanism
From phospholipid assembly to cellular uptake, liposomal technology follows a precise four-stage mechanism that maximizes nutrient absorption at every step.
Phosphatidylcholine molecules self-assemble into a bilayer structure identical to human cell membranes, creating hollow spherical vesicles 100–200nm in diameter through high-pressure homogenization.
The active ingredient — whether water-soluble (like Vitamin C) or fat-soluble (like CoQ10) — is trapped inside the aqueous core or within the lipid bilayer itself, achieving encapsulation efficiency above 85%.
The phospholipid shell shields the encapsulated nutrient from stomach acid (pH 1.5–3.5) and digestive enzymes, preventing the 60–90% degradation loss that affects standard oral supplements in the GI tract.
Because the liposome membrane is structurally identical to cell membranes, it fuses directly with intestinal epithelial cells through endocytosis, releasing the nutrient intracellularly for maximum systemic availability.
Proprietary Formulation Portfolio
Every formulation in the BL-LP series has been developed by Bionial's in-house R&D team with optimized phospholipid ratios, validated particle size distribution, and accelerated stability data. Private-label ready with your branding.
The Data Speaks for Itself
Published pharmacokinetic data consistently demonstrates that liposomal encapsulation delivers measurably higher plasma concentrations across every nutrient category tested.
| Nutrient | Standard Form | Liposomal Form | Improvement | Visual |
|---|---|---|---|---|
| Curcumin | ~2% oral bioavailability | ~58% via liposomal | 29× | |
| Glutathione | Poor oral stability (GSH degraded) | Intact cellular delivery | 4× | |
| Silymarin | ~23% oral bioavailability | ~100% via phytosome complex | 4.4× | |
| Iron | 5–15% (ferrous sulphate, with GI effects) | ~35–50% (ferric pyrophosphate liposomal) | 3.5× | |
| CoQ10 | ~3% oral (crystalline powder) | ~8% via liposomal | 2.5× | |
| Vitamin C | ~200mg max absorption (plateau) | ~1000mg sustained plasma levels | 1.5× |
Data sourced from published pharmacokinetic studies. Actual results may vary based on formulation design, particle size, and individual metabolism.
Built for Growth-Stage Brands
Liposomal technology is the single most effective way for supplement brands to differentiate from commodity competition and justify premium pricing.
In a market flooded with commodity capsules and tablets, liposomal products instantly position your brand in the premium tier. Consumers increasingly search for "liposomal" supplements on Amazon and D2C platforms — and they are willing to pay 2–4× more for proven superior absorption. Bionial's BL-LP series gives you market-ready liposomal SKUs without the years of R&D investment, letting you launch premium products in 30 days.
Pharmaceutical companies understand bioavailability — it is the language of drug development. Liposomal nutraceuticals bridge the gap between pharma-grade efficacy and the growing consumer wellness market. By offering clinically meaningful absorption improvements backed by pharmacokinetic data, your nutraceutical portfolio gains the scientific credibility that pharma brands demand. Bionial's WHO-GMP facility meets pharmaceutical manufacturing standards.
Classical Ayurvedic ingredients like Curcumin, Silymarin, and Ashwagandha extracts have well-documented bioavailability limitations. Liposomal encapsulation solves this without synthetic enhancers. Ayurvedic brands can now offer "traditional wisdom, modern delivery" — maintaining clean-label positioning while delivering measurably superior absorption. The BL-LP-07 Liposomal Curcumin (29× bioavailability) is purpose-built for this segment.
Inside Our Manufacturing Floor
Our liposomal manufacturing process follows pharmaceutical-grade protocols with rigorous quality control at every stage, ensuring consistent particle size, high encapsulation efficiency, and long-term stability.
We source pharmaceutical-grade phosphatidylcholine (PC) from non-GMO sunflower or soy lecithin with purity verification via HPLC. Every raw material batch undergoes identity testing, heavy metal screening, and microbiological analysis before release to production.
Active ingredients are dissolved or dispersed in aqueous phase, while phospholipids are hydrated in a controlled-temperature water bath. The two phases are combined under high-shear mixing to create a coarse pre-emulsion — the precursor to the final liposomal suspension.
The pre-emulsion passes through a high-pressure homogenizer at 800–1500 bar for multiple cycles. This reduces vesicle size to our target range of 100–200 nanometers, creating a uniform, stable liposomal suspension with narrow particle size distribution (PDI < 0.25).
Dynamic light scattering (DLS) analysis confirms mean particle diameter, polydispersity index, and zeta potential for every batch. Batches outside the validated 100–200nm window are recycled through the homogenizer. This is the critical quality gate that determines bioavailability performance.
HPLC quantification of free (unencapsulated) vs. entrapped active ingredient determines encapsulation efficiency. Our target: ≥85% encapsulation for all BL-LP formulations. Batches below threshold trigger root-cause investigation and reformulation adjustment.
Accelerated stability studies (40°C/75% RH for 6 months) and real-time stability protocols validate shelf life claims. Final release testing includes assay, dissolution, disintegration, microbial limits, and heavy metals — all documented in a comprehensive Certificate of Analysis (CoA) for each batch.
The Bionial Advantage
India has hundreds of nutraceutical manufacturers. Only one offers a complete, validated 8-SKU liposomal portfolio with in-house R&D and WHO-GMP certification under one roof.
No other manufacturer in the Mohali-Chandigarh-Punjab region offers a complete, validated liposomal product line. Our BL-LP series spans Iron, Calcium, Silymarin, CoQ10, Glutathione, Magnesium, Curcumin, and Vitamin C — covering every major therapeutic category from women's health to sports nutrition to derma.
Our formulation scientists have deep expertise in lipid-based drug delivery systems. Custom liposomal development includes particle size optimization (100–200nm), encapsulation efficiency validation (≥85%), stability testing (ICH-compliant), and bioavailability characterization. We do not outsource any step of the development process.
Our manufacturing plant in Mohali, Punjab holds WHO-GMP, FSSAI, and AYUSH GMP certifications. Every liposomal batch is manufactured under controlled cleanroom conditions with full batch documentation, CoA, and regulatory-ready dossiers for FSSAI product approval support.
From purchase order to dispatched product in 30 days. Our streamlined manufacturing process includes formulation confirmation (Day 1–3), bench sample (Day 4–7), sample approval (Day 8–12), pilot batch (Day 13–20), and full production with QC release (Day 21–30). No other liposomal manufacturer in India matches this speed.
Start with just 1,000 units per SKU for liquid formats and 3,000 for capsules. Liposomal products typically carry 3–5× the retail margin of standard supplements, making them the highest-ROI addition to any nutraceutical portfolio. Our low MOQ makes premium liposomal accessible to emerging brands without massive capital commitment.
We handle FSSAI product approval documentation, label compliance review, shelf-life validation, and claims substantiation for every liposomal SKU. Your brand launches with complete regulatory confidence — including FSSAI-compliant labelling, nutrition facts panels, and allergen declarations per Indian food safety regulations.
Common Questions
Detailed answers to the questions we hear most from brands evaluating liposomal supplement manufacturing.
Liposomal technology encapsulates active nutrients inside phospholipid vesicles (liposomes) that mirror the structure of human cell membranes. These nano-scale carriers — typically 100–200 nanometers in diameter — protect the nutrient from degradation in the stomach and intestines, allow it to pass through the gastrointestinal tract intact, and deliver its payload directly to cells through membrane fusion. The result is dramatically higher bioavailability: up to 29 times greater absorption compared to standard oral supplementation, as demonstrated in published pharmacokinetic studies. Originally developed for pharmaceutical drug delivery, liposomal technology has been adapted for nutraceuticals to solve the chronic bioavailability problem that limits the efficacy of conventional supplements.
The improvement varies by nutrient but is universally significant. Liposomal Curcumin achieves up to 29× the bioavailability of standard curcumin powder — making it the single most dramatic improvement in the Bionial BL-LP series. Liposomal Silymarin delivers approximately 4.4× higher liver uptake. Liposomal Glutathione increases systemic availability by roughly 4× compared to oral glutathione (which is normally almost entirely degraded in the GI tract). Liposomal Iron provides approximately 3.5× better absorption with zero GI side effects. Liposomal CoQ10 achieves about 2.5× higher plasma levels. Even Liposomal Vitamin C — which already has decent oral bioavailability — delivers approximately 1.5× higher sustained plasma concentrations. These are not theoretical numbers; they are derived from published clinical and pharmacokinetic data.
Absolutely. While the BL-LP series offers 8 ready-to-manufacture liposomal formulations for brands that want fast market entry, our in-house R&D team can develop fully custom liposomal products tailored to your specifications. This includes selecting specific active ingredients (including novel or proprietary compounds), optimizing phospholipid-to-active ratios for maximum encapsulation efficiency, adjusting particle size for target absorption profiles, and designing multi-nutrient combination formulas with synergistic co-factors. Custom development typically takes 6–10 weeks from brief to validated bench sample, followed by pilot batch validation and stability testing. Our team has experience formulating liposomal products for both hydrophilic (water-soluble) and lipophilic (fat-soluble) compounds.
Bionial offers liposomal supplement manufacturing with a minimum order quantity starting from 1,000 units per SKU for liquid formulations and 3,000 units for capsule formats. This is deliberately set low to make liposomal products accessible to D2C brands, emerging supplement companies, and Ayurvedic brands testing premium line extensions. Most competing liposomal manufacturers require 10,000–50,000 unit MOQs, which prices out early-stage brands. Our low MOQ combined with the premium retail pricing of liposomal products (typically 2–4× standard supplements) means brands can achieve positive unit economics from their very first batch.
Yes — liposomal formulations typically cost 30–60% more per unit than standard supplements. This premium reflects the cost of pharmaceutical-grade phospholipids, the specialized high-pressure homogenization equipment required, the additional quality control steps (particle size analysis, encapsulation efficiency testing), and the longer manufacturing cycle. However, the business case is overwhelmingly positive: liposomal products command 2–4× higher retail prices than standard supplements, resulting in significantly better gross margins despite higher COGS. Consumers actively seek out "liposomal" products and are willing to pay premium prices for clinically meaningful absorption improvements. For brands, liposomal is the single highest-ROI SKU category in the nutraceutical space.
Ready to Launch Premium?
Join the growing number of brands using Bionial's proprietary liposomal technology to differentiate, command premium pricing, and deliver clinically meaningful absorption to their consumers. Our team is ready to discuss your requirements.